Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
Titel:
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
Auteur:
Badar, Talha Kantarjian, Hagop M. Ravandi, Farhad Jabbour, Elias Borthakur, Gautam Cortes, Jorge E. Pemmaraju, Naveen Pierce, Sherry R. Newberry, Kate J. Daver, Naval Verstovsek, Srdan